Accurate, Needle-Free, MRI-based Detection of Ischemic Heart Disease without Contrast Agents
无需造影剂即可通过 MRI 进行准确、无针、基于 MRI 的缺血性心脏病检测
基本信息
- 批准号:10686342
- 负责人:
- 金额:$ 67.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-24 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAdenosineAdoptionAffectAmericanAmmoniaAngioplastyAnimal ModelAnimalsBrainBreathingCarbon DioxideCardiacCardiac Catheterization ProceduresCardiovascular systemCaringCause of DeathCessation of lifeClinicalContrast MediaCoronary Artery BypassCoronary StenosisCoronary arteryDataDetectionDevelopmentDiseaseEarly InterventionElectrocardiogramEnd stage renal failureEventExerciseFaceFundingGeneral PopulationHeartHospitalizationHypercapniaImageImpairmentInjectableIntravenousIonizing radiationIschemiaKineticsMagnetic Resonance ImagingMapsMeasurementMedicalMethodsMicrovascular DysfunctionMotionMyocardialMyocardial IschemiaMyocardiumNeedlesOperative Surgical ProceduresOxygenPartial PressurePatientsPerfusionPersonsPhysiologicalPositron-Emission TomographyPress ReleasesPrevalencePublishingRadialRadiationReportingResolutionRiskSafetyScienceSeveritiesSignal TransductionSpecificityStatistical AlgorithmStimulusStressStress TestsTestingThallium Myocardial Perfusion Imaging Stress TestTimeTranslatingTranslationsUnited StatesUnited States National Institutes of HealthValidationblood oxygen level dependentcardiac magnetic resonance imagingcardiovascular risk factorclinical translationclinically relevantclinically significantcompliance behaviorcomputer frameworkcoronary vasodilatorcost effectivedetection sensitivityforginghigh riskimage processingimprovedinformation gatheringinsightmortalitypharmacologicpreventprognostic valueprospectivereconstructionresearch clinical testingsingle photon emission computed tomographytargeted imaging
项目摘要
PROJECT SUMMARY
Ischemic heart disease (IHD) is the leading cause of death in the United States. It emanates from narrowing of
coronary arteries (CAD) and/or development of microvascular dysfunction culminating in myocardial ischemia
– a condition where the oxygen demand of the myocardium is far in excess of the available supply. IHD
accounts for more than 1 in 3 deaths and >1 million hospitalizations each year in the US. The extent and
severity of myocardial ischemia has been shown to provide incremental prognostic value over standard clinical
variables across the spectrum of presentation of patients with IHD. Long-established (SPECT or PET) and
more recently established (e.g., first pass-perfusion MRI) methods are routinely used to gather this information.
In spite of their capabilities, these methods have key limitations – they expose the patients to either ionizing
radiation or exogenous contrast agents, which carry risks to the patients. This is particularly a critical problem
in at least half a million patients with end-stage renal disease (ESRD) in the US. In ESRD patients, annual
ischemia testing is needed since the risk of cardiovascular mortality is > 10-fold greater than in the general
population. Hence there is an unmet and growing need for safe and reliable assessment of myocardial
ischemia in all patients, and is most pressing in ESRD patients, whose prevalence in the US is on the rise.
Blood-Oxygen-Level-Dependent (BOLD) Cardiac MRI (CMR) is a potential alternative to standard clinical
methods since it is free of ionizing radiation and exogenous contrast media. It also has the capability to provide
physiological insight into the disease based on measurements of impaired oxygen supply, and not from
surrogate metrics (wall motion, ECG changes, or contrast kinetics). Over the past two decades, the technical
capabilities of BOLD CMR have led to clinical testing. However, limitations in reliability (sensitivity, specificity
and accuracy) remain a major impediment for widespread clinical use of BOLD CMR. To overcome the
reliability limitations of BOLD CMR, in a previous R01 funding (2013 to 2017), we hypothesized that repeat
stimulations of the heart, analogous to brain activation studies using BOLD MRI (brain fMRI), could improve
the reliability of BOLD CMR. Subsequently, we went onto demonstrate that (i) a targeted change in arterial
partial pressure of CO2 (PaCO2) can be a potent non-invasive vasoactive stimulus; and a (ii) high-resolution,
whole heart BOLD CMR at 3T with repeat PaCO2 stimulation of the heart, when combined with a statistical
framework, can reliably detect BOLD signal changes in large, healthy, animals. To successfully translate the
promising impact of this BOLD CMR approach into the clinical arena, further advances and validation will be
required. This proposal aims to continue the successful advancement of this BOLD CMR approach towards
clinical feasibility so that it can enable a truly noninvasive and cost-effective ischemia testing that is free of
ionizing radiation, exogenous contrast agents, intravenous pharmacological agents or even needles. Thus, this
proposal is a critical step towards advancing the care of a large segment of IHD patients in the US.
项目总结
在美国,缺血性心脏病(IHD)是主要的死亡原因。它源于收窄了
冠状动脉(CAD)和/或最终导致心肌缺血的微血管功能障碍的发展
-心肌的需氧量远远超过可用供给量的情况。IHD
在美国,每年有超过1/3的死亡和100万人住院。范围和
心肌缺血的严重程度已被证明提供了比标准临床更高的预后价值。
IHD患者临床表现的不同变量。历史悠久的(SPECT或PET)和
最近建立的(例如,第一次通过-灌注MRI)方法被常规用于收集该信息。
尽管这些方法有其能力,但它们有关键的局限性--它们使患者暴露在电离或
放射或外源性造影剂,这会给患者带来风险。这是一个特别严重的问题
在美国至少50万终末期肾病(ESRD)患者中。对于终末期肾病患者,每年
由于心血管死亡的风险是一般情况下的10倍,因此需要进行缺血检测
人口。因此,对心肌梗死的安全和可靠评估的需求没有得到满足,而且还在不断增长。
缺血在所有患者中都存在,在终末期肾病患者中最为紧迫,其在美国的患病率正在上升。
血氧水平依赖(BOLD)心脏MRI(CMR)是一种潜在的替代标准临床
方法无电离辐射,无外源性造影剂。它还有能力为用户提供
对疾病的生理学洞察是基于对氧气供应受损的测量,而不是来自
替代指标(室壁运动、心电变化或对比动力学)。在过去的二十年里,技术上
BOLD CMR的能力已经导致了临床测试。然而,可靠性方面的限制(敏感性、特异性
和准确性)仍然是BOLD CMR广泛临床应用的主要障碍。要克服这个问题
大胆CMR的可靠性限制,在之前的R01资助(2013至2017年)中,我们假设重复
心脏的刺激,类似于使用BOLD MRI(脑功能磁共振成像)进行的大脑激活研究,可以改善
大胆的CMR的可靠性。随后,我们开始演示(I)动脉的靶向改变
二氧化碳分压(PaCO2)可以是有效的非侵入性血管活性刺激;以及(Ii)高分辨率,
全心在3T时大胆的CMR,当与统计学结合时,重复PaCO2刺激心脏
框架,可以可靠地检测大型健康动物的大胆信号变化。要成功地将
这一大胆的CMR方法有望在临床领域产生影响,进一步的进展和验证将是
必填项。这项提议旨在继续成功地推进这一大胆的CMR方法,以
临床可行性,以使其能够实现真正的非侵入性和成本效益的缺血测试,而不是
电离辐射、外源性造影剂、静脉注射药剂甚至针头。因此,这一点
该提案是推进美国大部分IHD患者护理的关键一步。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Disentangle, Align and Fuse for Multimodal and Semi-Supervised Image Segmentation.
- DOI:10.1109/tmi.2020.3036584
- 发表时间:2021-03
- 期刊:
- 影响因子:10.6
- 作者:Chartsias A;Papanastasiou G;Wang C;Semple S;Newby DE;Dharmakumar R;Tsaftaris SA
- 通讯作者:Tsaftaris SA
Artificial Intelligence for Contrast-Free MRI: Scar Assessment in Myocardial Infarction Using Deep Learning-Based Virtual Native Enhancement.
- DOI:10.1161/circulationaha.122.060137
- 发表时间:2022-11-15
- 期刊:
- 影响因子:37.8
- 作者:Zhang Q;Burrage MK;Shanmuganathan M;Gonzales RA;Lukaschuk E;Thomas KE;Mills R;Leal Pelado J;Nikolaidou C;Popescu IA;Lee YP;Zhang X;Dharmakumar R;Myerson SG;Rider O;Oxford Acute Myocardial Infarction (OxAMI) Study;Channon KM;Neubauer S;Piechnik SK;Ferreira VM
- 通讯作者:Ferreira VM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rohan Dharmakumar其他文献
Rohan Dharmakumar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rohan Dharmakumar', 18)}}的其他基金
Mechanistic Insights to A Translatable Therapy for Acute Reperfused Hemorrhagic Myocardial Infarctions
急性再灌注出血性心肌梗塞可转化疗法的机制见解
- 批准号:
10359807 - 财政年份:2020
- 资助金额:
$ 67.1万 - 项目类别:
Accurate, Needle-Free, MRI-based Detection of Ischemic Heart Disease without Contrast Agents
无需造影剂即可通过 MRI 进行准确、无针、基于 MRI 的缺血性心脏病检测
- 批准号:
9981378 - 财政年份:2020
- 资助金额:
$ 67.1万 - 项目类别:
Mechanistic Insights to A Translatable Therapy for Acute Reperfused Hemorrhagic Myocardial Infarctions
急性再灌注出血性心肌梗塞可转化疗法的机制见解
- 批准号:
9887771 - 财政年份:2020
- 资助金额:
$ 67.1万 - 项目类别:
Mechanistic Insights to A Translatable Therapy for Acute Reperfused Hemorrhagic Myocardial Infarctions
急性再灌注出血性心肌梗塞可转化疗法的机制见解
- 批准号:
10630055 - 财政年份:2020
- 资助金额:
$ 67.1万 - 项目类别:
Accurate, Needle-Free, MRI-based Detection of Ischemic Heart Disease without Contrast Agents
无需造影剂即可通过 MRI 进行准确、无针、基于 MRI 的缺血性心脏病检测
- 批准号:
10201743 - 财政年份:2020
- 资助金额:
$ 67.1万 - 项目类别:
Accurate, Needle-Free, MRI-based Detection of Ischemic Heart Disease without Contrast Agents
无需造影剂即可通过 MRI 进行准确、无针、基于 MRI 的缺血性心脏病检测
- 批准号:
10655692 - 财政年份:2020
- 资助金额:
$ 67.1万 - 项目类别:
Developing a MRI-guided Disease-Modifying Therapy for Post Infarction Chronic Heart Failure
开发 MRI 引导的梗死后慢性心力衰竭疾病缓解疗法
- 批准号:
9981537 - 财政年份:2017
- 资助金额:
$ 67.1万 - 项目类别:
Developing a MRI-guided Disease-Modifying Therapy for Post Infarction Chronic Heart Failure
开发 MRI 引导的梗死后慢性心力衰竭疾病缓解疗法
- 批准号:
9756228 - 财政年份:2017
- 资助金额:
$ 67.1万 - 项目类别:
4D SSFP MRI for Detecting Functionally Important Coronary Artery Stenosis at Rest
4D SSFP MRI 用于检测静息时具有重要功能的冠状动脉狭窄
- 批准号:
7837299 - 财政年份:2009
- 资助金额:
$ 67.1万 - 项目类别:
Reliable Evaluation of Coronary Artery Disease using Myocardial BOLD MRI with CO2
使用 CO2 心肌 BOLD MRI 可靠评估冠状动脉疾病
- 批准号:
8725722 - 财政年份:2008
- 资助金额:
$ 67.1万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 67.1万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 67.1万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 67.1万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 67.1万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 67.1万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 67.1万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 67.1万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 67.1万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 67.1万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 67.1万 - 项目类别:
Research Grant